Dr. Pramodkumar P. Sethi, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 386
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
NC license 2004-00969 -
Diagnostic Neuroimaging (Psychiatry & Neurology) Physician
NC license 2004-00969
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Moses H. Cone Memorial Hospital, the Greensboro, NC
- Alamance Regional Medical Center Burlington, NC
Medical groups
- Moses Cone Physician Services, Inc (406 clinicians)
- Moses Cone Affiliated Physicians, Inc. (80 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 386
- Services billed
- 668
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 110 | 99 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 103 | 72 |
| Critical care, first 30-74 minutes | 102 | 56 |
| Ultrasound of both sides of head and neck blood flow | 99 | 97 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 92 | 88 |
| New patient office or other outpatient visit, 45-59 minutes | 49 | 49 |
| Established patient office or other outpatient visit, 40-54 minutes | 35 | 32 |
| Hospital discharge day management, more than 30 minutes | 28 | 28 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 27 | 24 |
| Measurement of brain wave activity (eeg), awake and asleep | 24 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Memantine Hcl Other prescribers in Greensboro, NC | 121 |
| Topiramate Other prescribers in Greensboro, NC | 99 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Greensboro, NC | 88 |
| Donepezil Hcl Other prescribers in Greensboro, NC | 78 |
| Atorvastatin Calcium Other prescribers in Greensboro, NC | 67 |
| Gabapentin Other prescribers in Greensboro, NC | 56 |
| Levetiracetam Er (levetiracetam) Other prescribers in Greensboro, NC | 46 |
| Levetiracetam Other prescribers in Greensboro, NC | 41 |
| Rosuvastatin Calcium Other prescribers in Greensboro, NC | 33 |
| Repatha Sureclick (evolocumab) Other prescribers in Greensboro, NC | 28 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 27 companies reported 72 payments worth $3,883 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $2,468 |
|---|---|
| AbbVie Inc. | $278 |
| Medtronic, Inc. | $110 |
| UCB, Inc. | $110 |
| Sk Life Science, Inc. | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | $83.09 |
| Celgene Corporation | $61.69 |
| Bayer HealthCare Pharmaceuticals Inc. | $56.85 |
| Consulting Fee | $2,363 |
|---|---|
| Food and Beverage | $1,521 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Aug 27, 2025 | Consulting Fee | $2,363 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $280,504 in research payments for these studies, mostly to the institutions running them.
- A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK)
Janssen Research & Development, LLC - A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fi…
Janssen Research & Development, LLC - A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Eli Lilly and Company · Active, not recruiting · NCT04437511
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.